# Folinic Acid for Prevention of Pemetrexed-induced Toxicity

> **NCT06010277** · PHASE4 · UNKNOWN · sponsor: **Amphia Hospital** · enrollment: 50 (estimated)

## Conditions studied

- NSCLC
- Mesothelioma
- Thymoma

## Interventions

- **DRUG:** Folinic acid

## Key facts

- **NCT ID:** NCT06010277
- **Lead sponsor:** Amphia Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-06
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010277, "Folinic Acid for Prevention of Pemetrexed-induced Toxicity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06010277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*